HER3-Directed Antibody Therapy May Be an Effective Strategy in EGFR+ NSCLC
February 3rd 2021Patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, appeared to be effective at the recommended expansion dose of 5.6 mg/kg in patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer based on clinically meaningful antitumor activity and a manageable safety profile.
Ipatasertib, Paclitaxel Combo Does Not Improve PFS in PIK3CA/AKT1/PTEN-Altered TNBC
December 11th 2020Treatment with ipatasertib plus paclitaxel (Abraxane) failed to show a significant improvement in progression-free survival versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable, or metastatic triple-negative breast cancer.
Alpelisib/Letrozole Combo Sustains Efficacy in PIK3CA-Mutant HR+, HER2- Advanced Breast Cancer
December 11th 2020Combination treatment with alpelisib (Piqray) and letrozole (Femara) sustained efficacy and did not result in any new safety signals in patients with PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer who received prior treatment with the combination of a CDK4/6 inhibitor and fulvestrant (Faslodex).
Phase 3 EMPOWER-Lung 1 Shows Promise for Cemiplimab-rwlc in Advanced PD-L1+ NSCLC
September 23rd 2020Cemiplimab-rwlc (Libtayo) monotherapy led to a significant improvement in overall survival and progression-free survival in patients with advanced non-small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells.